 Home > Biochemistry News > Biotechnology News > BeiGene's Bispecific Antibody Therapy Approved in China to Treat Certain Childhood Leukemia

BeiGene's Bispecific Antibody Therapy Approved in China to Treat Certain Childhood Leukemia

 Last Update: 2022-05-08
 Source: Internet
 Author: User

Tags

surface antigen

refractory cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

A few days ago, BeiGene announced that the National Medical Products Administration (NMPA) of China has approved Belito (Belintoumumab for injection, English trade name Blincyto) for the treatment of children with relapsed or refractory (R/R) CD19-positive precursor B-cell acute lymphoblastic leukemia (ALL)

Petrito was developed by Amgen, and BeiGene obtained its authorization in China according to the global oncology strategic cooperation reached by the two parties in 2020

Acute lymphoblastic leukemia (ALL) is a rapidly progressive hematologic and myeloid tumor that affects both adults and children

Belitox is a bispecific T cell engager (BiTE) immuno-oncology therapy that binds to the CD19 antigen expressed on the surface of B-lineage cells

The prior conditional approval of Bilito for the treatment of adult patients with relapsed or refractory CD19-positive precursor B-cell ALL was based on data from clinical trials conducted outside of China and based on Phase 3 clinical trials conducted in adult patients in China.

References:

[1] BeiGene announced the approval of Bélito® (belintuumab for injection) in China for the treatment of children with relapsed or refractory precursor B-cell acute lymphoblastic leukemia

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.